Literature DB >> 18809177

Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men.

Beatrice G Sjöberg1, Jun Su, Ingrid Dahlbom, Hans Grönlund, Max Wikström, Bo Hedblad, Göran Berglund, Ulf de Faire, Johan Frostegård.   

Abstract

BACKGROUND: Natural antibodies specific for phosphorylcholine (anti-PC) have been implicated as protective factors in atherosclerosis. We herein determined the relationship between IgM anti-PC and incidence of cardiovascular disease (CVD).
METHODS: We studied 349 incident cases (200 men) of first events of CVD (coronary heart disease (CHD; n=203 or ischemic stroke; n=146) and 693 age- and sex-matched controls identified through 12 years of follow-up (1991-2003) of subjects from the cardiovascular cohort within the Malmö Diet and Cancer Study. Relative risks (RR) of CVD with 95% confidence intervals (CI) of incident CVD with adjustments for age, smoking, total cholesterol and blood pressure were determined. Anti-PC-levels were measured using ELISA (Athera CVDefine).
RESULTS: As determined using Athera CVDefine, significant associations were attained with values of anti-PC below 17U/ml (corresponding to the lowest 9th percentile), which remained after taking confounders into account (RR: 1.79, 95% CI: 1.09-2.94, p=0.021). If men were studied separately, significance was evident at values below 17U/ml (RR: 2.01, 95% CI: 1.11-3.67, p=0.022), which was not the case among women. Furthermore, values below 17U/ml were also associated with ischemic stroke (RR=3.67, 95% CI: 1.34-10.1, p=0.01), but not with CHD.
CONCLUSION: Low IgM anti-PC could be a novel risk marker for development of ischemic stroke in men. Further studies are needed to establish gender and subgroup differences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809177     DOI: 10.1016/j.atherosclerosis.2008.07.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  36 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

Review 2.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

3.  Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.

Authors:  Calvin Yeang; Devin Hasanally; Xuchu Que; Ming-Yow Hung; Aleksandra Stamenkovic; David Chan; Rakesh Chaudhary; Victoria Margulets; Andrea L Edel; Masahiko Hoshijima; Yusu Gu; William Bradford; Nancy Dalton; Phuong Miu; David Yc Cheung; Davinder S Jassal; Grant N Pierce; Kirk L Peterson; Lorrie A Kirshenbaum; Joseph L Witztum; Sotirios Tsimikas; Amir Ravandi
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

4.  Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.

Authors:  Christian A Gleissner; Christian Erbel; Julia Haeussler; Mohammadreza Akhavanpoor; Gabriele Domschke; Fabian Linden; Andreas O Doesch; Göran Conradson; Sebastian J Buss; Nina P Hofmann; Gitsios Gitsioudis; Hugo A Katus; Grigorios Korosoglou
Journal:  Clin Res Cardiol       Date:  2014-08-08       Impact factor: 5.460

Review 5.  A Special Connection between γδ T Cells and Natural Antibodies?

Authors:  Willi K Born; Yafei Huang; Wanjiang Zeng; Raul M Torres; Rebecca L O'Brien
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2016-05-27       Impact factor: 4.291

6.  In old BALB/c mice, bone marrow pre-B cell and surrogate light chain reduction is associated with increased B cell reactivity to phosphorylcholine, but reduced T15 idiotype dominance.

Authors:  Kelly Khomtchouk; Sarah Alter; Michelle Ratliff; Bonnie B Blomberg; Richard L Riley
Journal:  Mech Ageing Dev       Date:  2016-11-19       Impact factor: 5.432

7.  Metabolites as novel biomarkers for childhood obesity-related traits in Mexican-American children.

Authors:  V S Farook; L Reddivari; G Chittoor; S Puppala; R Arya; S P Fowler; K J Hunt; J E Curran; A G Comuzzie; D M Lehman; C P Jenkinson; J L Lynch; R A DeFronzo; J Blangero; D E Hale; R Duggirala; J Vanamala
Journal:  Pediatr Obes       Date:  2014-11-18       Impact factor: 4.000

8.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

9.  Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.

Authors:  Bram J Geller; Jessica L Mega; David A Morrow; Jianping Guo; Elaine B Hoffman; C Michael Gibson; Christian T Ruff
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

10.  Rheumatoid cachexia is associated with dyslipidemia and low levels of atheroprotective natural antibodies against phosphorylcholine but not with dietary fat in patients with rheumatoid arthritis: a cross-sectional study.

Authors:  Ann-Charlotte Elkan; Niclas Håkansson; Johan Frostegård; Tommy Cederholm; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2009-03-10       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.